Skip to main content
Premium Trial:

Request an Annual Quote

Sanguine BioSciences Closes Seed Funding Round

NEW YORK (GenomeWeb News) – Biospecimen firm Sanguine BioSciences announced on Thursday the closing of its seed funding round.

The round was led by Invent Ventures and Heliant Ventures and will be used to further build Sanguine's infrastructure, it said. Sanguine did not disclose the amount of the funding.

Based in Valencia, Calif., the company serves essentially as a conduit between researchers who require high-quality biospecimens and research subjects who can supply them. It "engages" subjects by using social media and then schedules blood draws, which are then processed into DNA, RNA, cells, plasma, and serum to be used by pharmaceutical firms and research organizations in their work.

Sanguine said it has created an infrastructure that informs research subjects about how their biosamples are used "in order to ultimately increase trust and information flow back to researchers."

The seed funding will go toward further development of Sanguine's internal infrastructure to "safely and efficiently collect, process, document, and store up to 1,000 blood samples each moth across the West Coast," Co-Founder and CEO Brian Neman said in a statement.

He added that revenues and the number of research subjects have seen "significant growth" since the end of last year, and "[t]he successful completion of the laboratory and regulatory infrastructure allowed us the opportunity to open our doors to research participants, both healthy, and diagnosed with an ailment(s), and to researchers at numerous pharmaceutical companies and academic institutions."

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.